Last checked at 
(Alliance News) - Abingdon Health PLC on Tuesday said it has signed a "significant" European contract to supply components for a Covid-19 rapid antigen test.
Shares in the lateral flow test developer and manufacturer were trading 20% higher in London on Tuesday morning at 11.67 pence.
Abingdon said that the contract is for an initial period of 12 months with an option to extend. There is also an option to expand to other aspects of device manufacture.
The contract is with an unnamed European customer and the initial phase is worth a minimum of GBP2.7 million.
Chief Executive Chris Yates said: "The contract highlights the strengths of Abingdon's flexibility in being able to offer a range of first-class contract services across primary and secondary production."
By Sophie Rose; sophierose@alliancenews.com
Copyright 2022 Alliance News Limited. All Rights Reserved.
